Abstract
After a gap of almost 60 years following the development of warfarin, 2 new categories of oral anticoagulant agents have been approved for clinical use – the direct thrombin inhibitors and factor Xa inhibitors. These agents promise to be more convenient to administer with fixed dosing but still have equivalent efficacy and improved bleeding risk compared to warfarin. The clinical community is looking forward to the widespread usage of these agents but there is also some apprehension regarding bleeding risks, non-availability of specific reversal strategies and lack of specific monitoring parameters. This review article will attempt to educate the reader about three representative drugs from these classes: Dabigatran, Rivaroxaban and Apixaban. We will discuss the historical perspective to the development of these drugs, available research data and pharmacology of these agents. The best strategies for monitoring and reversal of these drugs in special situations will also be touched upon.
Keywords: Acute coronary syndrome, apixaban, atrial fibrillation, dabigatran, deep venous thrombosis, pulmonary embolism, rivaroxaban, venous thromboembolism, DVT, HIT
Current Cardiology Reviews
Title:Newer Oral Anticoagulant Agents: A New Era in Medicine
Volume: 8 Issue: 2
Author(s): Ramil Goel and Komandoor Srivathsan
Affiliation:
Keywords: Acute coronary syndrome, apixaban, atrial fibrillation, dabigatran, deep venous thrombosis, pulmonary embolism, rivaroxaban, venous thromboembolism, DVT, HIT
Abstract: After a gap of almost 60 years following the development of warfarin, 2 new categories of oral anticoagulant agents have been approved for clinical use – the direct thrombin inhibitors and factor Xa inhibitors. These agents promise to be more convenient to administer with fixed dosing but still have equivalent efficacy and improved bleeding risk compared to warfarin. The clinical community is looking forward to the widespread usage of these agents but there is also some apprehension regarding bleeding risks, non-availability of specific reversal strategies and lack of specific monitoring parameters. This review article will attempt to educate the reader about three representative drugs from these classes: Dabigatran, Rivaroxaban and Apixaban. We will discuss the historical perspective to the development of these drugs, available research data and pharmacology of these agents. The best strategies for monitoring and reversal of these drugs in special situations will also be touched upon.
Export Options
About this article
Cite this article as:
Goel Ramil and Srivathsan Komandoor, Newer Oral Anticoagulant Agents: A New Era in Medicine, Current Cardiology Reviews 2012; 8 (2) . https://dx.doi.org/10.2174/157340312801784934
DOI https://dx.doi.org/10.2174/157340312801784934 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Onion Extract on Endogenous Vascular H2S and Adrenomedulin in Rat Atherosclerosis
Current Pharmaceutical Biotechnology Cellular Mechanisms of Valvular Thickening in Early and Intermediate Calcific Aortic Valve Disease
Current Cardiology Reviews TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
Current Pharmaceutical Biotechnology Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Chemistry and Pharmacology of Natural Catechins from <i>Camellia sinensis</i> as Anti-MRSA Agents
Current Topics in Medicinal Chemistry Review of Cell and Organ Printing Patents
Recent Patents on Biomedical Engineering (Discontinued) Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Implications of Pharmacogenetics for Oral Anticoagulants Metabolism
Current Drug Metabolism Heart Failure in South America
Current Cardiology Reviews The Role of (Modified) Lipoproteins in Vascular Function: A Duet Between Monocytes and the Endothelium
Current Medicinal Chemistry Radionuclide Imaging in Drug Development
Current Pharmaceutical Design Potential Use of Dendritic Cells for Anti-Atherosclerotic Therapy
Current Pharmaceutical Design Advanced Cardiac Imaging of Radiation-induced Injury - a Review
Current Medical Imaging A Stress Repair Mechanism That Maintains Vertebrate Structure During Stress
Cardiovascular & Hematological Disorders-Drug Targets Antibiotic Susceptibility and Treatment of Brucellosis
Recent Patents on Anti-Infective Drug Discovery The Pathophysiology of Heart Failure in Children: The Basics
Current Cardiology Reviews Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design How to Recognize Epicardial Origin of Ventricular Tachycardias?
Current Cardiology Reviews